Bristol-Myers Squibb (BMY) – Trade Idea

Company Description

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company’s products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. Source: Reuters

Charts

Option Pricing

  • Implied Volatility (expected price movement) for short-dated options is 27%
  • Realized Volatility (historic price movement) for short-dated options is 25%
  • Implied Volatility Percentile for short-dated options is 44%

Trade Idea

Yesterday’s close price triggered a long momentum signal based on one of our proprietary strategies. If you are bullishly disposed, you may want to consider the following trade structure:

SideQtyExpStrikeType
Buy118 Oct50Call

TRADE MANAGEMENT

50 %
Profit Target

Trade Structure Profit Target.

50 %
Premium Stop

Close the Trade Structure after if the fair market value is <50% of Net Debit Paid.

This website is a general communication being provided for informational purposes only. It is educational in nature and not designed to be a recommendation for any specific investment product, strategy, plan feature or other purposes. By receiving this communication you agree with the intended purpose described above. Any examples used in this material are generic, hypothetical and for illustration purposes only. None of EQT Media, its affiliates or representatives is suggesting that the recipient or any other person take a specific course of action or any action at all. Communications such as this are not impartial and are provided in connection with the advertising and marketing of products and services. Prior to making any investment or financial decisions, an investor should seek individualized advice from a personal financial, legal, tax and other professional advisors that take into account all of the particular facts and circumstances of an investor’s own situation. Opinions and statements of financial market trends that are based on current market conditions constitute our judgment and are subject to change without notice. We believe the information provided here is reliable but should not be assumed to be accurate or complete. The views and strategies described may not be suitable for all investors. This communication may not be redistributed or retransmitted, in whole or in part, or in any form or manner, without the express written consent of EQT Option. Any unauthorized use or disclosure is prohibited. Receipt and review of this information constitutes your agreement not to redistribute or retransmit the contents and information contained in this communication without first obtaining express permission from an authorized officer of EQT Option.